Skip to main content
EMNEastman Chemical CompanyBuy Wait5.8·$66.75
EMN · Why this verdict

Why Eastman Chemical (EMN) is rated BUY WAIT

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictBUY WAIT
Overall score5.8/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis

Engine thesis — one sentence

Eastman Chemical screens attractively on price-to-earnings and PEG metrics, but a Piotroski F-Score of 3 out of 9, no competitive moat, and revenue declining 5% year-over-year indicate the cheapness reflects genuine fundamental weakness; with less than 1% upside remaining to the analyst price target, the risk/reward offers almost no margin of safety.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

At less than 1% below the analyst consensus price target, virtually all the expected return from current levels has already been captured, while downside to technical support leaves a risk/reward ratio of 0.15-to-1.

↓Deteriorating
Price targets
Expectation
Either a price correction or a meaningful analyst target revision restores upside above 10% within 12 months.

CounterThe two most recent quarters produced earnings beats, which could prompt upward analyst target revisions that widen the upside without requiring a price decline.

Despite a forward P/E of 10.7x and a PEG of 0.64 suggesting inexpensive pricing, the underlying business quality falls below the minimum acceptable threshold, with a Piotroski F-Score of 3 out of 9 signaling broad financial weakness and no identifiable competitive moat to protect future earnings.

→Stable
Quality breakdown
Expectation
Over 12 months, the Piotroski F-Score rises above 6 out of 9, confirming broad improvement in solvency, profitability, and operating efficiency.

CounterA cyclical trough in specialty chemical spreads can temporarily depress financial-strength metrics; if commodity demand recovers, quality indicators could snap back faster than the current score implies.

Revenue has contracted 5% year-over-year with earnings growth contributing nothing positive, removing the fundamental catalyst that would normally justify a re-rating even from a depressed valuation.

→Stable
Growth breakdown
Expectation
Revenue growth turns positive year-over-year for at least 2 consecutive quarters, demonstrating that the demand environment has stabilized.

CounterIndustrial chemical volumes can recover sharply with downstream demand; the 5% revenue decline may already be fully priced into the forward P/E of 10.7x.

After back-to-back misses in the second half of 2025, the two most recent quarters each produced earnings beats, suggesting the pace of operational deterioration may be moderating even while the underlying business quality remains weak.

↓Deteriorating
Earnings
Expectation
The beat streak extends to 4 consecutive quarters by year-end 2026, with average earnings surprise turning meaningfully positive.

CounterTwo beats following two misses is a thin base; if industrial demand softens further, the miss pattern could resume without any change to the weak structural fundamentals.

Per-dimension breakdown

Value

7.8/10data confidence 100%
ComponentSub-score
P/E7.3
P/S9.8
EV/EBITDA6.5
Fwd P/E9.3
PEG9.2
Analyst target5.0
  • ▸Forward P/E: 10.0x
  • ▸PEG: 0.64
  • ▸Attractively valued

Quality

4.2/10data confidence 100%
ComponentSub-score
ROE2.4
ROA2.4
Gross margin0.0
Op margin5.2
Net margin2.5
Current ratio5.5
FCF quality9.1
Moat4.2
Piotroski F6.7
  • ▸Excellent cash conversion: 123% FCF/NI
  • ▸No competitive moat

Growth

6.8/10data confidence 67%
ComponentSub-score
Rev growth5.0
EPS growth8.5

Momentum

6.0/10data confidence 100%
ComponentSub-score
RSI2.9
MACD10.0
OBV10.0
MA position7.2
Volume0.0
  • ▸Overbought bear rally (RSI 72)
  • ▸Volume accumulation (rising OBV)
  • ▸Below 200-MA but MA still rising (+0.7%/30d) — pullback in uptrend, not confirmed weakness

Sentiment

6.8/10data confidence 100%
ComponentSub-score
LLM sentiment6.3
Analyst rating7.3
Price target6.8

Insider

5.2/10data confidence 50%
ComponentSub-score
materiality5.0
holder change5.4
  • ▸Negligible insider selling — $234,111 (0.003% of mkt cap)

Peer rank

5.2/10data confidence 80%
ComponentSub-score
value rank7.8
quality rank4.8
growth rank5.2

Technical

3.0/10data confidence 100%
ComponentSub-score
bollinger0.5
support resistance1.9
52w position6.6

Risk (lower is worse)

5.3/10data confidence 100%
ComponentSub-score
short interest6.3
days to cover6.1
volatility7.1
put call0.0
implied vol5.2
beta6.7
debt equity5.7
  • ▸Elevated put/call: 5.40

Catalyst

5.3/10data confidence 100%
ComponentSub-score
erm5.0
earnings history6.7
earnings timing5.0
surprise avg4.1
dividend safety4.8
news activity6.0
  • ▸Strong earnings: 3B/1M
  • ▸Earnings today
  • ▸Yield trap warning: high yield but unsafe

How the verdict was assembled

Engine trigger

Earnings today. Wait until post-earnings.

Engine technical detail
verdict_path: L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BAND
Passed (5)
  • MOMENTUM:6.0>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • ASYMMETRY:0.2<1.5@spot
  • EARNINGS_PROXIMITY:0d<=7d
Warning (0)

none

Reward-to-Risk
0.16
Upside
+1.2%
Downside
7.5%
Sizing output
STARTER

Setup— — No clear chart pattern; technical signals are mixed

EdgeSector Rotation — Basic Materials sector out of favor, value=7.8

SuitabilityModerate — Balanced profile

Investment implication

A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Value at 7.8 (strongest), but ASYMMETRY:0.2<1.5@spot also fails — the news block is the proximate trigger, not the sole driver.

The strongest dimensions are Value at 7.8, Growth at 6.8, and Sentiment at 6.8; the weakest are Technical at 3.0, Quality at 4.2, and Peer rank at 5.2. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 0.16 and an engine sizing output of STARTER.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Quality Deficit Below Minimum

    Trip ifPiotroski F-Score rises above 6 out of 9 for 2 consecutive quarters, indicating quality has genuinely recovered.

  • P2Revenue Contraction Limits Rerating

    Trip ifRevenue growth turns positive above 3% year-over-year for 2 consecutive quarters.

  • P3Exhausted Upside Near Target

    Trip ifAnalyst consensus price target is revised above $90, restoring upside greater than 20% from the current price.

  • P4Nascent Earnings Stabilization

    Trip ifEPS surprise falls below 0% in either of the next 2 quarterly reports, breaking the nascent beat streak.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › EMN › Why this verdict